ProQR Therapeutics N.V.

NASDAQ: PRQR · Real-Time Price · USD
1.69
0.07 (4.32%)
At close: May 19, 2025, 2:28 PM

ProQR Therapeutics Statistics

Share Statistics

ProQR Therapeutics has 105.21M shares outstanding. The number of shares has increased by 28.84% in one year.

Shares Outstanding 105.21M
Shares Change (YoY) 28.84%
Shares Change (QoQ) 1.95%
Owned by Institutions (%) 54.38%
Shares Floating n/a
Failed to Deliver (FTD) Shares 162,156
FTD / Avg. Volume 27.28%

Short Selling Information

The latest short interest is 376.04K, so 0.36% of the outstanding shares have been sold short.

Short Interest 376.04K
Short % of Shares Out 0.36%
Short % of Float 0.46%
Short Ratio (days to cover) 1

Valuation Ratios

The PE ratio is -7.53 and the forward PE ratio is -3.23. ProQR Therapeutics's PEG ratio is 2.63.

PE Ratio -7.53
Forward PE -3.23
PS Ratio 11.05
Forward PS 1.5
PB Ratio 2.36
P/FCF Ratio -5.53
PEG Ratio 2.63
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for ProQR Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.95, with a Debt / Equity ratio of 0.19.

Current Ratio 3.95
Quick Ratio 3.95
Debt / Equity 0.19
Debt / EBITDA -0.71
Debt / FCF -0.46
Interest Coverage -28.29

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $113,885.54
Profits Per Employee $-167,246.99
Employee Count 166
Asset Turnover 0.11
Inventory Turnover n/a

Taxes

Income Tax -197K
Effective Tax Rate 0.7%

Stock Price Statistics

The stock price has increased by -15.98% in the last 52 weeks. The beta is 0.35, so ProQR Therapeutics's price volatility has been higher than the market average.

Beta 0.35
52-Week Price Change -15.98%
50-Day Moving Average 1.5
200-Day Moving Average 2.3
Relative Strength Index (RSI) 53.43
Average Volume (20 Days) 594,333

Income Statement

In the last 12 months, ProQR Therapeutics had revenue of 18.91M and earned -27.76M in profits. Earnings per share was -0.34.

Revenue 18.91M
Gross Profit 18.91M
Operating Income -30.47M
Net Income -27.76M
EBITDA -24.12M
EBIT -26.88M
Earnings Per Share (EPS) -0.34
Full Income Statement

Balance Sheet

The company has 149.41M in cash and 17.22M in debt, giving a net cash position of 132.19M.

Cash & Cash Equivalents 149.41M
Total Debt 17.22M
Net Cash 132.19M
Retained Earnings -427.16M
Total Assets 151.69M
Working Capital 104.36M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -36.39M and capital expenditures -1.42M, giving a free cash flow of -37.81M.

Operating Cash Flow -36.39M
Capital Expenditures -1.42M
Free Cash Flow -37.81M
FCF Per Share -0.46
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -161.18% and -146.86%.

Gross Margin 100%
Operating Margin -161.18%
Pretax Margin -147.9%
Profit Margin -146.86%
EBITDA Margin -127.6%
EBIT Margin -161.18%
FCF Margin -200.01%

Dividends & Yields

PRQR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for PRQR is $9, which is 452.1% higher than the current price. The consensus rating is "Buy".

Price Target $9
Price Target Difference 452.1%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score -2.31
Piotroski F-Score 3